Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS , Kranc KR , Helgason GV ,Huntly BJP, Gallipoli P. Inhibition of mannose metabolism sensitizes acute myeloid leukemia cells to therapy by directing ferroptotic cell death.Nat Common. 2023 April 14;14(1):2132.
Agrawal-Singh S, Bagri J, Giotopoulos G, Azazi DMA, Horton SJ, Lopez CK, Anand S, Bach AS, Stedham F, Antrobus R, Houghton JW, Vassiliou GS, Sasca D, Yun H, Whetton AD,Huntly BJP. HOXA9 forms a repressive complex with the nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.Blood. December 28, 2022: blood.2022016528.
Meduri E, Breeze C, Marando L, Richardson SE,Huntly BJP. The landscape of RNA editing in acute myeloid leukemia reveals associations with disease mutations and clinical outcomes.iScience. 2022 Nov 17;25(12):105622.
Dawson MA, Borthakur G,Huntly B, Karadimitris A , Cheerful A , Chaidos A , Vogl DT , Pollyea DA , Davies FE , Morgan GJ , Glass J , Kamdar M , Matthews Butter MV , Tovar N , Yeh P , Garcia Thin R , Basheer F , Marando L , Gallipoli P , Wyce A , Krishnatry AS , Barbash O , Bakirtzi E , Ferron-Brady G , Karpinich NO , McCabe MT , Foley SW , Horner T , Dhar A , Kremer BE , Dickinson M. Phase I/II open-label trial for the treatment of relapsing/ resistant hematological malignancies.Clin Cancer Res. October 9, 2022: CCR-22-1284.
Yun H, Vohra S, Lara-Astiaso D,Huntly BJP.Integration of multiomic data to reveal chromatin remodeling and reorganization induced by synergy of gene mutations.STAR Protocol. Oct 13, 2022;3(4):101770.
Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, Dillon R, Levine MF, Leongamornlert D, Butler A, Ganser A, Bullinger L, Döhner K, Ottmann O, Adams R, Döhner H, Campbell PJ, Burnett AK, Dennis M, Russell NH, Devlin SM,Huntly BJP*, Papaemmanuil E*. Unified classification and risk stratification in acute myeloid leukemia.Nat Common. August 8, 2022;13(1):4622. * Shared senior authors
Gupta S, Dovey OM, Domingues AF, Cyran OW, Cash CM, Giotopoulos G, Rak J, Cooper J, Gozdecka M, Dijkhuis L, Asby RJ, Al-Jabery N, Hernandez-Hernandez V, Prabakaran S,Huntly BJ, Vassiliou GS, Pina C. Transcriptional variation accelerates pre-leukaemic state by cell diversification and disruption of protein synthesis.adv. exact sciences. Aug 5, 2022;8(31):eabn4886.
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F,Huntly BJStegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Inhibition of cystine uptake enhances first-line therapies in acute myeloid leukemia.Leukemia. April 26, 2022
Narayan N.Huntly BJP. Targeting AML at the intersection of epigenetics and signaling.Scientific signal. 2022 April 19;15(730):eabo0059.
Anderson GSF, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, So T, Bloxham D, Aubareda A, Asby R, Walker I, Jenkinson L, Soilleux EJ, Roy JP, Teodosio A, Ficken CL, Officer-Jones L, Nasser S, Skerget S, Keats J, Greaves P, Tai YT, Anderson KC, MacFarlane M, Thaventhiran JE.Huntly BJP, PJ Lehner, MA Chapman. Unbiased cell surface proteomics identifies SEMA4A as an effective target for myeloma immunotherapy.Blood. February 8, 2022: blood.2021015161.
Arede L, Foerner E, Wind SS, Kulkarni R, Domingues AF, Giotopoulos G, Kleinwächter S, Mollenhauer-Starkl M, Davison H, Chandru A, Asby R, Samarista R, Gupta S, Forte D, Curti A, Scheer E,Huntly BJP, Tora L, Pina C. KAT2A ATAC and SAGA complexes play a unique role in cell maintenance and identity in hematopoiesis and leukemia.adv. blood. October 15, 2021: BloodAdvances.2020002842.
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo - Venzor A, Wang X, Gallipoli P, Muller-Tidow C, Osborne CS, Vassiliou GS,Huntly BJP. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.Nata Genet. Oct 2021;53(10):1443-1455.
Lara-Astiaso,Huntly BJP. Protein condensates provide a platform to control chromatin.Nature. 2021 Sep 15;597, 642-644.
Richardson SE,Huntly BJP.Targeting chromatin regulation in acute myeloid leukemia.Hemisphera. June 1, 2021;5(6):e589.dwa: 10.1097/HS9.0000000000000589.
Cao H, Neerincx A, de Bono B, Lakner U, Huntington C, Elvin J, Gudgin E, Pridans C, Vickers MA,Huntly B, Trowsdale J, Barrow A.D. Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalized cell surface antigen expressed by acute myeloid leukemia cells.Br J Haematol. Jun 2021;193(5):946-950.doi: 10.1111/bjh.17496.
Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S,Huntly B, Clark RE, Thomas IF, Kjeldsen L, McMullin MF, Drummond M, Kell J, Spearing R. J. Clin Oncol. Determining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three and four courses. J Clin Oncol. March 10, 2021;39(8):890-901. doi: 10.1200/JCO.20.01170.
Marando L,Huntly BJP.BETs need greens: folic acid deficiency and resistance to MYC-targeted therapies.Discovery of Cancer 2020 Dec;10(12):1791-1793. doi: 10.1158/2159-8290.CD-20-1333.
Burrows N, Bashford-Rogers RJM, Bhute VJ, Peñalver A, Ferdinand JR, Stewart BJ, Smith JEG, Deobagkar-Lele M, Giudice G, Connor TM, Inaba A, Bergamaschi L, Smith S, Tran MGB, Petsalaki E, Lyons PA, Zaklęcie M,Huntly BJP, Smith KGC, Cornall RJ, Clatworthy MR, Maxwell PH.Dynamic regulation of hypoxia-induced factor 1α activity is essential for normal B cell development.Nat Immunol. 2020 lis;21(11):1408-1420. doi: 10.1038/s41590-020-0772-8.
Forte D, Garcia-Fernandez M, Sanchez-Aguilera A, Stavropoulou V, Fielding C, Martin-Perez D, Lopez JA, Costa ASH, Tronci L, Nikitopoulou E, Barber M, Gallipoli P, Marando L, Fernandez de Castillejo CL, Tzankov A, Dietmann S, Cavo M, Catani L, Curti A, Vazquez J, Frezza C,Huntly BJ, Schwaller J, Mendez-Ferrer S.Bone marrow mesenchymal stem cells support the bioenergetics of acute myeloid leukemia and enhance antioxidant defense and chemotherapy escape.Cell Metabolism 2020 September 16: S1550-4131(20)30479-4. doi: 10.1016/j.cmet.2020.09.001.
Au YZ, Gu M, De Braekeleer E, Gozdecka M, Aspris D, Tarumoto Y, Cooper J, Yu J, Ong SH, Chen X, Tzelepis K,Huntly BJP, Vassiliou G, Yusa K. KAT7 is a genetic susceptibility to acute myeloid leukemias driven by MLL rearrangements. Leukemia. August 6, 2020 doi: 10.1038/s41375-020-1001-z.
Giotopoulos G,Huntly BJP. CML: new tools to answer old questions. Blood. 2020 Jun 25;135(26):2327-2328. doi: 10.1182/blog.2020005599.
Marando L,Huntly BJP. The molecular landscape of acute myeloid leukemia: prognostic and therapeutic implications. Curr Oncol 2020 Representative Jun 1;22(6):61. doi: 10.1007/s11912-020-00918-7.
Lang KM, Harrison KL, Williamson PR,Huntly BJP, Ossenkoppele G, Geissler J, Bereczky T, Hernández-Rivas JM, Chevrou-Séverac H, Goodbody R, Schulze-Rath R, Bullinger L. Baseline measurement result set for future clinical trials in acute myeloid leukemia: HARMONY study protocol using process Delphi based on multi-stakeholder consensus and final consensus meeting. Trials. 2020 May 27;21(1):437. doi: 10.1186/s13063-020-04384-1.
Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, Drummond M,Huntly B, Marshall S, McMullin MF, Neelakantan P, Raghavan M, Sivakumaran M, Tighe J, Wandroo F, Willis F, Glen F, Fildes L, Collington SJ, Ryan J, Clark RE, Mead AJ. Real-world tyrosine kinase inhibitor treatment pathways, monitoring and response patterns in UK chronic myelogenous leukemia patients: UK TARGET CML study. Br J Haematol. 2020 May 24. doi: 10.1111/bjh.16733.
Basilico S, Wang X, Kennedy A, Tzelepis K, Giotopoulos G, Kinston SJ, Quiros PM, Wong K, Adams DJ, Carnevalli LS,Huntly BJP, Vassiliou GS, Calero-Nieto FJ, Göttgens B. Analysis of the early stages of MLL-induced leukemic transformation using a mouse model of AML. Nat Commune. 2020 March 16;11(1):1407. doi: 10.1038/s41467-020-15220-0.
Domingues AF, Kulkarni R, Giotopoulos G, Gupta S, Vinnenberg L, Arede L, Foerner E, Khalili M, Adao RR, Johns A, Tan S, Zeka K,Huntly BJ, Prabakaran S, Pina C. Loss of Kat2a increases transcriptional noise and depletes acute myeloid leukemia stem cells.elife. 2020 sty 27;9. pii: e51754. doi: 10.7554/eLife.51754.
Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Daphni U, de Vries EGE, Ghia P, Gökbuget N, Gonzalez-Calle V,Huntly B, Jäger U , Latino NJ , Douillard JY , Malcovati L , Mateos MV , Ossenkoppele GJ , Porkka K , Raderer M MD , Ribera JM , Scarfò L , Wester R , Zygoura P , Sonneveld P. EHA ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.ESMO Open. 2020 January;5(1). fri: e000611. doi: 10.1136/esmoopen-2019-000611.
Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, Ghetti M, Stengel A, Guadagnuolo V, De Tommaso R, Papayannidis C, Robustelli V, Franchini E, Rorà AGLD, Ferrari A, Fontana MC, Bruno S, Ottaviani E, Soverini S, Storlazzi CT, Haferlach C, Sabattini E, Testoni N, Iacobucci I,Huntly BJP, Ficarra E, Martinelli G. Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia.Cancer (Basel). December 5, 2019;11(12). Fri: E1951. doi: 10.3390/raki11121951.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS,Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ. Genetic modification of primary human B cells to model high-grade lymphoma.Nat Common. Oct 4, 2019;10(1):4543. doi: 10.1038/s41467-019-12494-x.
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P,Huntly BJP. Cohesin-dependent regulation of gene expression during differentiation is lost in myeloid tumors with cohesin mutation.Blood. Dec 12, 2019;134(24):2195-2208. doi: 10.1182/krew.2019001553.
Horton S.,Huntly BJP. Kinase networks regulate metabolism: I'D(H1) never guessed!The discovery of cancerJune 2019;9(6):699-701.doi:10.1158/2159-8290.CD-19-0373.
Lu Y, Stuart JH, Talbot-Cooper C, Agrawal-Singh S,Huntly B, Smid AI, Snowden JS, Dupont L, Smith GL. Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded by vaccinia virus C6 protein.Proc Natl Acad Sci U S A. Jun 11, 2019;116(24):11997-12006. doi: 10.1073/pnas.1816399116.
Basheer F , Giotopoulos G , Meduri E , Yun H , Mazan M , Sasca D , Gallipoli P , Marando L , Gozdecka M , Asby R , Sheppard O , Dudek M , Bullinger L , Döhner H , Dillon R , Freeman S , Ottmann O , Burnett A , Russell N , Papaemmanuel E , Hills R , Campbell P , Vassiliou GS .Huntly BJP. Contrasting demands during disease evolution identify EZH2 as a therapeutic target in AML.J Exp Med. 2019 Apr 1;216(4):966-981. doi: 10.1084/em.20181276.
Gallipoli P,Huntly BJP. Histone modifiers are oxygen sensors.Science. 2019 15 marca;363(6432):1148-1149. doi: 10.1126/science.aaw8373.
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC,Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS. SRPK1 maintains acute myeloid leukemia by affecting the use of epigenetic regulator isoforms, including BRD4.Nat Common. Dec 19, 2018;9(1):5378. doi: 10.1038/s41467-018-07620-0.
Gallipoli P,Huntly BJP. Prognostic models Turn on heat (IT).flt3ITD-Mutated AML.Clin Cancer Res. 2019 Jan 15;25(2):460-462. two: 10.1158/1078-0432.CCR-18-3146.
Giotopoulos G,Huntly BJPIntratumor heterogeneity: tools to understand and exploit the clone wars in AML.Cancer cell. Oct 8, 2018;34(4):533-535. doi: 10.1016/j.ccell.2018.09.004.
Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ,Huntly BJP, Martincorena I, Anderson E, O'Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ. Population dynamics of normal human blood inferred from somatic mutations.Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0.
Marando L,Huntly BJP. Hematopoietic stem cells made BETTER by inhibition.Hematology. Jun 2018;103(6):919-921. doi: 10.3324/hematol.2018.193706.
Gozdecka M , Meduri E , Mazan M , Tzelepis K , Dudek M , Knights AJ , Pardo M , Yu L , Choudhary JS , Metzakopian E , Iyer V , Yun H , Park N , Varela I , Bautista R , Collord G , Dovey O , Garyfallos DA , De Braekeleer E , Kondo S , Cooper J , Gottgens B , Bullinger L , Northcott PA , Adams D , Vassiliou GSHuntly BJP. UTX-mediated enhancer and chromatin remodeling inhibit myeloid leukemogenesis through non-catalytic inverse regulation of ETS and GATA programs.Nata Genet. Jun 2018;50(6):883-894. two: 10.1038/s41588-018-0114-z.
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C,Huntly BJP. Glutaminolysis is a metabolic dependency in FLT3ITDacute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.Blood. April 12, 2018;131(15):1639-1653. doi: 10.1182/blood-2017-12-820035.
Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E,Huntly BJP, Jacobsen S.E.W., Mead A.J. Ezh2 and Runx1 mutations work together to initiate lymphomyelogenous leukemia in early thymic progenitors.Cancer cell. Feb 12, 2018;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.
Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ,Huntly BJPEarly loss of Crebbp imparts malignant stem cell properties to lymphoid progenitors. Natcell biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597.
Gallipoli P,Huntly BJP.New epigenetic therapies in hematological malignancies: the current state and beyond. seminarCancer Biol. August 4, 2017 Fri: S1044-579X(17)30135-9. doi: 10.1016/j.semcancer.2017.07.005.
Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X,Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE A four-gene LincRNA expression signature predicts risk in multiple cohorts of patients with acute myeloid leukemia. Leukemia. July 4, 2017. doi: 10.1038/leu.2017.210.
Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U,Huntly B,The new Green TA signaling screen shows that CALR mutations activate essential MAPK signaling and facilitate the differentiation of megakaryocytes.Leukemia. 2016 December 2nd two: 10.1038/leu.2016.280.
Tzelepis K , Koike-Yusa H , De Braekeleer E , Li Y , Metzakopian E , Dovey OM , Mupo A , Grinkevich V , Li M , Mazan M , Gozdecka M , Ohnishi S , Cooper J , Patel M , McKerrell T , Chen B , Domingues AF , Gallipoli P , Teichmann S , Ponstingl H , McDermott U , Saez-Rodriguez J ,Huntly BJ, Iorio F, Pina C, Vassiliou GS, Yusa KA CRISPR Dropout Screen identifies genetic gaps and therapeutic targets in acute myeloid leukemia. Cellrepresentative. Oct 18, 2016;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.
Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V , Gottlieb E , Franze K ,HuntlyB, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C. Fumarate is an epigenetic modifier that induces epithelial-mesenchymal transition. Nature. Aug 31, 2016;537(7621):544-547. doi: 10.1038/natura19353.
Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SE,Huntly BJ, Ottersbach K.Mll-AF4 provides enhanced self-renewal and lymphoid potential during a limited window of development. Cellrepresentative. July 6, 2016 Fri: S2211-1247(16)30800-2. doi: 10.1016/j.celrep.2016.06.046.
Sasca D,Huntly BJ.Independence of epigenetic and genetic variation in AML. NatZ. Jul 7, 2016;22(7):708-9. two: 10.1038/nm.4136.
[ PubMed ] [ Cross Ref ] Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC , Ghisi M , Smil D , Carpenter C , Brown P , Garton N , Blewitt ME , Bannister AJ , Kouzarides T ,Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA. Functional interplay of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. June 13, 2016. doi: 10.1038/nsmb.3249.
McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J , Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R,Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS. Development and validation of a comprehensive tool for genomic diagnosis of myeloid malignancies. Blood. April 27, 2016 Fri: blood-2015-11-683334.
Grimwade D, Ivey A,Huntly BJ. The molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. Jan 7, 2016;127(1):29-41. doi: 10.1182/blood-2015-07-604496.
Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morrison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, [ PubMed ] Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ,Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA.BET inhibitor resistance emerges from leukemia stem cells. Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/natura14888.
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ,Huntly BJA new mouse model identifies cooperating mutations and therapeutic targets critical for the progression of chronic myelogenous leukemia. J ExpZ. Sep 21, 2015;212(10):1551-69. doi: 10.1084/em.20141661.
van der Weyden L, Giotopoulos G, Wong K, Rust AG, Robles-Espinoza CD, Osaki H,Huntly BJ, Adams DJ.Somatic drivers from B-ALL in the ETV6-RUNX1 model; Pax5(+/-) leukemia. BMCRak. August 13, 2015;15:585. doi: 10.1186/s12885-015-1586-1.
Basheer F,Huntly BJBromodomain .BET inhibitors in leukemia. To the power ofHematol. Aug 2015;43(8):718-31. doi: 10.1016/j.expem.2015.06.004.
Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA,Huntly BJ. CBP and p300 epigenetic regulators facilitate leukemogenesis and are therapeutic targets in acute myeloid leukemia. Oncogene. April 20, 2015. doi: 10.1038/onc.2015.92.
Dawson MA , Gudgin EJ , Horton SJ , Giotopoulos G , Meduri E , Robson S , Cannizzaro E , Osaki H , Wiese M , Putwain S , Fong CY , Grove C , Craig J , Dittmann A , Lugo D , Jeffrey P , Drewes G , Lee K , Bullinger L , Prinjha RK , Kouzarides T , Vassiliou GS ,Huntly BJ. Recurrent mutations including NPM1c activate the BRD4-dependent core transcription program in acute myeloid leukemia. Leukemia. Feb 2014;28(2):311-20. doi: 10.1038/leu.2013.338.
Wyspiański BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA,Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T. Inhibition of BET protein shows efficacy against JAK2V617F-driven tumors. Leukemia. Jan 2014;28(1):88-97. doi: 10.1038/leu.2013.234.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D,Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with unmutated JAK2. N English J Med. Dec 19, 2013;369(25):2391-405. doi: 10.1056/NEJMoa1312542.
Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J,Huntly BJ, Gottgens B. HOX-mediated expression of LMO2 in the embryonic mesoderm is recapitulated in acute leukemias. Oncogene. Nov 28, 2013;32(48):5471-80. doi: 10.1038/onc.2013.175.
Bashford-Rogers RJ, Palser AL,Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P. Network properties derived from deep sequencing of human B cell receptor repertoires demarcate B cell populations. Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113.
Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Seconds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M,Huntly B, Bradley A, Vassiliou GS. Detailed molecular characterization of karyotyped acute myeloid leukemia using targeted DNA capture. Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117.
Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS , Oliver J , Wong JW , Gottgens B ,Huntly BJ, Pimanda JE. Heptad activity of transcription factors is associated with stem cell programs and clinical outcomes in acute myeloid leukemia. Blood. Mar 21, 2013;121(12):2289-300. doi: 10.1182/blood-2012-07-446120.
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G,Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Cancer Nat Rev. Nov 2012;12(11):767-75. doi: 10.1038/nrc3368.
Grimwade L, Gudgin E, Bloxham D, Bottley G, Vassiliou G,Huntly B, Scott MA, Erber WN. Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. Cytometry A. 2012 Oct;81(10):896-900. doi: 10.1002/cyto.a.22116.
Anand S.,Huntly BJ. Disrupted signaling in myeloproliferative neoplasms. Hematol Oncol Clin North Am. Oct 2012;26(5):1017-35. doi: 10.1016/j.hoc.2012.07.004.
Dawson MA, Kouzarides T,Huntly BJ. Targeting epigenetic readers in cancer. N English J Med. 2012 Aug 16;367(7):647-57. doi: 10.1056/NEJMra1112635.
Horton SJ,Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. hematology. Jul 2012;97(7):966-74. doi: 10.3324/hematol.2011.054734.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE , Auger KR , Mirguet O , Doehner K , Delwel R , Burnett AK , Jeffrey P , Drewes G , Lee K ,Huntly BJ*, Kuzarides T*. Inhibition of BET recruitment to chromatin as an effective treatment for MLL fusion leukemia. Nature. 2011 478(7370):529-33.
*joint senior authors
Chan WI, Dawson MA, Hannah R, Paul D, Pridans C, Joshi A, Gottgens B, Van Deursen JI.Huntly BJP. The transcriptional co-activator Cbp controls hematopoietic stem cell quiescence and multipotent differentiation. Mol Cell Biol. Dec 2011;31(24):5046-60. Epub 2011 October 17.
Anand S, Stedham FE, Beer PA, Gudgin E, Bench AJ, Green AR,Huntly BJP. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood. Aug 11, 2011;118(6):1610-21. Epub 2011 June 8.
van der Weyden L, Giotopolous G, Rust AG, Matheson L, van Delft F, Kong J, Corcoran A,Huntly BJ*, Adams DJ*. Modeling the evolution of ETV6-RUNX1-induced acute lymphoblastic leukemia in mice. Blood. 2011; 118(4):1041-51. Epub 2011 May 31.
*joint senior authors
Anand S, Stedham FE, Gudgin E, Beer PA, Bench AJ, Erber W, Green AR,Huntly BJP. Effect of JAK2 mutation on hematopoietic and progenitor compartment in human myeloproliferative neoplasms. Blood. 2011; 118(1):177-81. Epub 2011 May 11.
Kvinlaug BT, Chan WI, Bullinger L, Sears C, Paul D, Okabe R, Lee BH, Benner A, De Silva I, Valk P, Delwel R, Armstrong SA, Döhner H, Gilliland DG,Huntly BJP. Common and overlapping pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011; 71(12):4117-29. Epub 2011 April 19.
Li P, Burke S, Chen X, Ortiz M, Lee SC, Lu D, Campos L, Dougan G,Huntly BJPGottgens B, Jenkins N, Copeland NC, Colucci F, Liu P. Reprogramming of T cells to natural killer-like cells after removal of Bcl11b. Science. July 2, 2010; 329(5987):85-9.
Vezzoli A, Bonadies N, Allen MD, Freund SM, Santiveri CM, Kvinlaug BT,Huntly BJ, Göttgens B, Bycroft M. Molecular basis of histone H3K36me3 recognition by the PWWP Brpf1 domain. Nat Struct Mol Biol. May 2010;17(5):617-9.
Zhao R, Follows GA, Beer PA,Huntly BJP, Green AR, Alexander DR. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders N Engl J Med. 2008; 359(26): 2778-89.
Scholl C, Bansal D, Döhner K, Eiwen K,Huntly BJP, Lee BH, Rücker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S. The CDX2 homeobox gene is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest. 2007 Apr. 2;117(4):1037-1048.
Tothova Z, Kollipara R,Huntly BJ, Lee BH, Catrillion D, Passegue E, Cullen D, McDowell E, Lazo-Kallanian S, Williams I, DePinho R, Gilliland DG. FoxO are critical mediators of stem cell resistance to physiological cell oxidative stress. 2007 Jan 26;128(2):325-39.
Lee BH, Tothova Z, Levine RL, Anderson K, Cullen DE, McDowell EP, Adelsperger J,Huntly BJP, Beran M, Jacobsen SE, Gilliland DG. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a mouse model of chronic myelomonocytic leukemia. Cancer cell. 2007;12:367-80.
Bansal D, Scholl C, Frohling S, McDowell E, Lee BH, Dohner K, Ernst P, Davidson A, Daley GQ, Zon LI, Gilliland DG,Huntly BJP. Cdx4 upregulates Hox gene expression and generates acute myeloid leukemia alone and in collaboration with Meis1a in a mouse model. Proc Natl Acad Sci USA 2006; 103:16924-9.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G,Huntly BJP,Boggon TJ, Włodarska I, Clark JJ, Moore S, Adelsberger J, Koo S, Lee J, Gabriel S, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WJ, Meyerson M, Golub TR , Lee SJ, Gilliland DG. Activation of JAK2 tyrosine kinase mutations in polycythemia vera, essential thrombocythaemia and myeloid metaplasia with myelofibrosis. Cancer cell. 2005; 7: 387-397.
Huntly BJP, Shigematzu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. MOZ-TIF2, but not BCR-ABL, confers leukemic stem cell properties to committed murine hematopoietic progenitors. Cancer cell. 2004; 6: 586-595.